Skip to main content
. Author manuscript; available in PMC: 2014 Nov 1.
Published in final edited form as: Ann Surg Oncol. 2013 Jul 31;20(12):3862–3868. doi: 10.1245/s10434-013-3168-2

Figure 4. Treatment with MK-2206 causes no concomitant inhibition of RET (Rearranged during Transfection) activity in medullary thyroid cancer cells (MTC-TT).

Figure 4

Total RET protein levels are stable in MTC-TT lysates isolated after 4 days of treatment with MK-2206 (0–10 µM). Select phosphorylation residues (pRETY905 and pRETY1062) actually increase with treatment, indicating RET activity is not blocked by MK-2206 treatment. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as a loading control.